Disproportionate utilization of healthcare resources among veterans with COPD: a retrospective analysis of factors associated with COPD healthcare cost

Cost Effectiveness and Resource Allocation

Ralph J Panos²  Zhouyang Weng¹  Alok Kumar Dwivedi¹  Kyle Darnell² 

[1] Division of Biostatistics and Epidemiology, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA;Pulmonary, Critical Care, and Sleep Medicine Division, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA

关键词: Cost;    Healthcare utilization;    Veterans healthcare administration;    COPD;   

Others  :  810653
DOI  :  10.1186/1478-7547-11-13

 received in 2012-12-03, accepted in 2013-05-24,  发布年份 2013

【 摘 要 】

Background

COPD is a significant cause of morbidity and mortality in the Veterans Health Administration (VHA). To determine the clinical factors associated with the cost of COPD management, we analyzed the relationship between clinical characteristics and COPD healthcare costs at the Cincinnati VAMC.

Methods

We queried the VHA Decision Support System for patients diagnosed with COPD at the Cincinnati VAMC and calculated their VHA COPD-related encounters and costs in FY2008. Patients were ranked by COPD-related cost. We determined the detailed clinical characteristics of patients selected by modified systematic sampling and performed univariate and multivariable ordinary linear regression analysis to determine factors associated with cost.

Results

3263 Veterans had 11,869 encounters with a primary or secondary diagnosis of COPD: 10,032 clinic visits, 505 emergency department (ED) visits, and 1,332 hospitalizations and incurred a total COPD-related healthcare cost of $21.4 M: $2.4 M clinic visits, $0.21 M ED visits, and $18.7 M hospitalizations and $0.89 M for COPD-related prescription costs. When the patients were ranked by VHA healthcare costs, the top 20% of patients accounted for 86% of the total costs and 57% of the total encounters with a primary or secondary diagnosis code of COPD and 90% of the total costs and 75% of the total encounters with a primary diagnosis code of COPD. The clinical characteristics and VHA healthcare costs of 840 of the 3263 unique individuals with COPD were analyzed to determine those characteristics associated with increased COPD-related costs. Univariate analysis showed significant associations with 24 clinical variables; the 4 most highly associated factors were nursing home residence, total hospital admissions, use of oral corticosteroids, and supplemental oxygen (p < 0.001 for all). In multivariate analysis, total number of admissions (p < 0.001), management by a pulmonologist (p < 0.001), number of clinic visits (p < 0.001), use of short acting anticholinergic (p = 0.001), forced expiratory volume in 1 second (FEV1) (p = 0.011), number of prescriptions (p = 0.011), body mass index (BMI) (p = 0.025), and use of inhaled corticosteroid (p = 0.043) were associated with COPD management cost.

Conclusion

The total number of admissions, clinic visits, physiologic impairment, BMI, number of medications, and type of provider are strongly associated with the total cost of COPD management. These factors may be used to focus COPD management toward patients with the potential for high utilization of healthcare resources.

【 授权许可】

   
2013 Darnell et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Murphy D, Chaudhry Z, Almoosa K, Panos R: High prevalence of chronic obstructive pulmonary disease among veterans in the urban midwest. Mil Med 2011, 176(5):552-560.
• [2]McDonald M, Hertz R: Prizer Facts: Utilization of Verterans Affairs Medical Care Services by United States Veterans. The University of HawaI’I System. May 2003. Available at: http://www.hawaii.edu/hivandaids/Utilization%20of%20Veterans%20Affairs%20Medical%20Care%20Services%20by%20US%20Veterans.pdf webcite. Accessed June 2012
• [3]Committe On Veterans’ Affairs: House Commitee on Veterans Affairs. November 6, 2010. http://archives.veterans.house.gov/Media/File/111/9-29-10health/VARepQFR.htm webcite. Accessed June 2012
• [4]Seemungal T, Donaldson G, Bhowmik A, Jeffries D, Wedzicha J: Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000, 161(5):1608-1613.
• [5]Seemungal T, Donaldson G, Paul E, Bestall J, Jeffries D, Wedzicha J: Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998, 157(5 Pt 1):1418-1422.
• [6]Connors AJ, Dawson N, Thomas C, et al.: Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am J Respir Crit Care Med 1996, 154(4 Pt 1):959-967.
• [7]Cao Z, Ong K, Eng P, Tan W, Ng T: Frequent hospital readmissions for acute exacerbation of COPD and their associated factors. Respirology 2006, 11(2):188-195.
• [8]Hilleman D, Dewan N, Malesker M, Friedman M: Pharmacoeconomic evaluation of COPD. Chest 2000, 118(5):1278-1285.
• [9]Wilson L, Devine E, So K: Direct medical costs of chronic obstructive pulmonary disease: chronic bronchitis and emphysema. Respir Med 2000, 94(3):204-213.
• [10]Niewoehner D, Lokhnygina Y, Rice K, et al.: Risk indexes for exacerbations and hospitalizations due to COPD. Chest 2007, 131(1):20-28.
• [11]Osman I, Godden D, Friend J, Legge J, Douglas JG: Quality of life and hospital re-admission in patients with chronic obstructive pulmonary disease. Thorax 1997, 52(1):67-71.
• [12]Garcia-Aymerich J, Barreiro E, Farrero E, RM M, Morera J, Anto J: Patients hospitalized for COPD have a high prevalence of modifiable risk factors for exacerbation (EFRAM study). Eur Respir J 2000, 16(6):1037-1042.
• [13]Lau A, Yam L, Poon E: Hospital re-admission in patients with acute exacerbation of chronic obstructive pulmonary disease. Respir Med 2001, 95(11):876-884.
• [14]Gudmundsson G, Gislason T, Janson C, et al.: Risk factors for rehospitalisation in COPD: role of health status, anxiety and depression. Eur Respir J 2005, 26(3):414-419.
• [15]Garcia-Americh J, Farrero E, Felez M, et al.: Risk factors of readmission to hospital for a COPD exacerbation: a prospective study. Thorax 2003, 58(2):100-105.
• [16]Garcia-Aymerich J, Monso E, Marrades R, et al.: Risk factors for hospitalization for a chronic obstructive pulmonary disease exacerbation. EFRAM study. Am J Respir Crit Care Med Sep 2001, 164(6):1002-1007.
• [17]Erelel M, Cunhadaroglu C, Ece T, Arseven O: The frequency of deep venous thrombosis and pulmonary embolus in acute exacerbation of chronic obstructive pulmonary disease. Respir Med 2002, 96(7):515-518.
• [18]Greene C, Bradley K, Bryson C, et al.: The association between alcohol consumption and risk of COPD exacerbation in a veteran population. Chest 2008, 134(4):761-767.
• [19]Blamoun A, Batty G, DeBari V, Rashid A, Sheikh M, Khan M: Statins may reduce episodes of exacerbation and the requirement for intubation in patients with COPD: evidence from a retrospective cohort study. Int J Clin Pract 2008, 62(9):1373-1378.
• [20]Rohde G, Wiethege A, Borg I, et al.: Respiratory viruses in exacerbations of chronic obstructive pulmonary disease requiring hospitalisation: a case–control study. Thorax 2003, 58(1):37-42.
• [21]Quint J, Baghai-Ravary R, Donaldson G, Wedzicha J: Relationship between depression and exacerbations in COPD. Eur Respir J 2008, 32(1):53-60.
• [22]McGhan R, Radcliff T, Rish R, Sutherland E, Welsh C, Make B: Predictors of rehospitalization and death after a severe exacerbation of COPD. Chest 2007, 132(6):1748-1755.
• [23]Kessier R, Faller M, Fourgaut G, Meenecier B, Weitzenblum E: Predictive factors of hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999, 159(1):158-164.
• [24]Marin J, Carrizo S, Casanova C, et al.: Prediction of risk of COPD exacerbations by the BODE index. Respir Med 2009, 103(3):373-378.
• [25]Groenewegen K, Postma D, Hop W, et al.: Increased systemic inflammation is a risk factor for COPD exacerbations. Chest 2008, 133(2):350-357.
• [26]Hurst J, Vestbo J, Anzueto A, et al.: Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010, 363:1128-1138.
• [27]Sharafkhaneh A, Petersen N, Yu HJ, Dalal A, Johnson M, Hanania N: Burden of COPD in a government health care system: a retrospective observational study using data from the US Veterans Affairs population. Int J COPD 2010, 5:125-132.
• [28]Yu W, Ravelo A, Wagner T, et al.: Prevalence and costs of chronic conditions in the VA health care system. Med Care Res Rev 2003, 60(3 Suppl):146S-167S.
• [29]Wouters E: Economic analysis of the Confronting COPD survey: an overview of results. Respir Med 2003, 97(Suppl C):S3-S14.
• [30]Menzin J, Boulanger L, Marton J, et al.: The economic burden of chronic obstructive pulmonary disease (COPD) in a U.S. Medicare population. Respir Med 2008, 102(9):1248-1256.
• [31]Simon-Tuval T, Scharf S, Maimon N, Bernhard-Scharf B, Reuveni H, Tarasiuk A: Determinants of elevated healthcare utilization in patients with COPD. Respir Res 2011., 12(7)
• [32]Shaya F, Lin P, Aljawadi M, Scharf S: Elevated economic burden in obstructive lung disease patients with concomitant sleep apnea syndrome. Sleep Breath 2009, 13(4):317-323.
• [33]Akazawa M, Jalpern R, Riedel A, Stanford R, Dalal A, Blanchette C: Economic burden prior to COPD diagnosis: a matched case–control study in the United States. Respir Med 2008, 102(12):1744-1752.
• [34]Mapel D, Robinson S, Dastani H, Shah H, Phillips A, Lydick E: The direct medical costs of undiagnosed chronic obstructive pulmonary disease. Value Health 2008, 11(4):628-636.
• [35]Stanton M, Rutherford M: The high concentration of U.S. health care expenditures. Rockville (MD): Agency for Healthcare Research and Quality; 2005. Pub. No. 06–0060
• [36]Teo W, Tan WS, Chong W, et al.: Economic burden of chronic obstructive pulmonary disease. Respirology 2012, 17(1):120-126.
• [37]Masa J, Sobradillo V, Villasante C, et al.: Costs of chronic obstructive pulmonary disease in Spain. Estimation from a population-based study. Arch Bronconeumol 2004, 40(2):72-79.
• [38]Jacobson L, Hertzman P, Lofdahl C, Skogh B, Lindgren B: The economic impact of asthma and chronic obstructive pulmonary disease (COPD) in Sweden in 1980 and 1991. Respir Med 2000, 94(3):247-255.
• [39]Elizhauser A, Au D, Podulka J: Readmissions for Chronic Obstructive Pulmonary Disease, 2008. Rockville, MD: Agency for Healthcare REsearch and Quality; 2011. HCUP Statistical Brief #121
• [40]Miravitlles M, Murio C, Guerrero T, Gisber R, EPOC DSGDsAyFel: Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest 2002, 121(5):1449-1455.
• [41]Dal Negro R, Berto P, Tognella S, Quareni L: Global outcomes in lung disease study group. Cost-of-illness of lung disease in the TriVeneto region, Italy: the GOLD study. Monaldi Arch Chest Dis 2002, 57(1):3-9.
• [42]Miravilles M, Murio C, Guerrero T, Gisbert R: Costs of chronic bronchitis and COPD: a 1-year follow-up study. Chest 2003, 123(3):784-791.